Q2 FY2026 · ended Jun 30, 2026 · Revenue $145.00M, +2.1% YoY · Filed Jul 31, 2026
Moderna, Inc. (MRNA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $145.0 million and a net loss of $782.0 million. Free cash flow was -$563.0 million. As of Jun 30, 2026 it held $6.9 billion in cash and investments and $1.3 billion in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MRNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1682852
- Former names
- Moderna Therapeutics, Inc. (until Aug 24, 2016)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $145.0M | $389.0M | $678.0M | $1.0B | $142.0M |
| Operating income | -$815.0M | -$1.4B | -$857.0M | -$260.0M | -$907.0M |
| Net income | -$782.0M | -$1.3B | -$826.0M | -$200.0M | -$825.0M |
| Diluted EPS | -$1.97 | -$3.40 | -$2.11 | -$0.51 | -$2.13 |
| Operating cash flow | -$526.0M | -$630.0M | $930.0M | -$847.0M | -$919.0M |
| Free cash flow | -$563.0M | -$692.0M | $891.0M | -$880.0M | -$922.0M |
| Total assets | $11.0B | $11.5B | $12.3B | $12.1B | $12.0B |
| Total liabilities | $4.2B | $4.1B | $3.7B | $2.8B | $2.6B |
| Stockholders' equity | $6.8B | $7.4B | $8.7B | $9.3B | $9.4B |
| Cash and investments | $6.9B | $7.5B | $8.1B | $6.6B | $7.5B |
| Total debt | $1.3B | $1.3B | $1.3B | $734.0M | $741.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Sep 1, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Jul 31, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 31, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 8, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 11, 2026 | May 6, 2026 |
All 1002 Moderna, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.